Microbiome Derived Metabolism and Pharmacokinetics

Description

The investigators will perform single-dose pharmacokinetic (PK) studies in humans following administration of drugs with known microbiome derived metabolism (MDM) in parallel with preclinical studies. By directly comparing laboratory measurements to clinical results, the investigators will be able to confirm the relevance of MDM in vivo, create microbiome-dependent PK profiles of the MDM positive drugs, and establish methodology to capture the contribution of MDM to inter-individual variability in clinical drug PK profiles.

Conditions

Microbial Colonization

Study Overview

Study Details

Study overview

The investigators will perform single-dose pharmacokinetic (PK) studies in humans following administration of drugs with known microbiome derived metabolism (MDM) in parallel with preclinical studies. By directly comparing laboratory measurements to clinical results, the investigators will be able to confirm the relevance of MDM in vivo, create microbiome-dependent PK profiles of the MDM positive drugs, and establish methodology to capture the contribution of MDM to inter-individual variability in clinical drug PK profiles.

Incorporating Drug Metabolism by the Human Gut Microbiome Into Personalized Medicine

Microbiome Derived Metabolism and Pharmacokinetics

Condition
Microbial Colonization
Intervention / Treatment

-

Contacts and Locations

Somerville

Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey, United States, 08876

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 18 to 65 years of age
  • * Body mass index between 18.5 - 29.9 kg/m2
  • * Estimated creatinine clearance \< 50 mL/min
  • * Liver impairment (liver enzymes \> 2 times upper limit)
  • * Antibiotics in the past 3 months
  • * History of gastrointestinal disease
  • * History of autoimmune disorder
  • * Chronic viral infection
  • * Smoker
  • * Alcohol intake (defined as having up to 1 drink per day for women and up to 2 drinks per day for men)
  • * Use of immune modulating medications
  • * Diabetes mellitus
  • * Any history or contraindication to the study medications
  • * Additional exclusion criteria will be based on the FDA approved prescribing information for selected drugs (i.e., contraindications)

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Rutgers, The State University of New Jersey,

Study Record Dates

2025-12-31